
Please try another search
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Name | Age | Since | Title |
---|---|---|---|
George S. Golumbeski | 66 | 2018 | Independent Chairman of the Board |
Neil W. Gibson | 67 | 2016 | Independent Director |
Helen Marie Boudreau | 57 | 2020 | Independent Director |
Tyler Brous | 40 | 2016 | Lead Independent Director |
Taylor H. Schreiber | 44 | 2016 | Co-Founder, CEO & Director |
Clay B. Siegall | 63 | 2024 | Independent Director |
Carrie Brownstein | 54 | 2021 | Independent Director |
Giorgos Bamias | - | - | Member of Advisory Board |
Fabio Cominelli | - | - | Member of Advisory Board |
Kate A. Sasser | 47 | 2024 | Independent Director |
Eddie Wang | - | - | Member of Advisory Board |
Ayman Al-Shamkhani | - | - | Member of Advisory Board |
Mick Croft | - | - | Member of Advisory Board |
Michael Stewart Lee | 45 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review